Technical Resources International, Inc.

Technical Resources International, Inc., doing business as Technical Resources Intl, is a minority-owned, woman-owned, Hispanic American-owned small business headquartered in Bethesda, Maryland, that delivers clinical research support, regulatory affairs, and biomedical research services to federal health agencies as a prime contractor. The vendor competes in full-and-open federal procurement across 27 customer agencies without set-aside restrictions, holding a portfolio anchored by four major indefinite delivery contracts valued at $1.26 billion combined ceiling and a fifth single-award IDV worth $2.5 million with the National Institute on Drug Abuse. TRI operates predominantly as a prime contractor—425 of 427 recent awards are prime—with minimal subcontractor engagement (3% sub-hours share across SCI-reportable prime contracts).

TRI's customer concentration is stark and drives nearly all dollars. The National Institute of Allergy and Infectious Diseases (NIAID) dominates by potential value—45 awards carrying $2.57 billion combined ceiling, or 50% of TRI's entire five-year portfolio. The National Cancer Institute (NCI) is second at 12 awards worth $1.35 billion combined potential value, and the Office of the Assistant Secretary for Preparedness and Response (ASPR) ranks third with 8 awards totaling $910.2 million. These three agencies alone account for roughly 96% of TRI's combined potential value, making them the driving force of the business. By award count, NIAID leads (45 awards), followed by the National Institute on Drug Abuse (19 awards, $48.5 million) and NCI (12 awards). The Environmental Protection Agency and Federal Emergency Management Agency each show high award counts (100 and 109 awards respectively) but carry minimal dollar value—these are publication, media, or administrative service task orders. The concentration risk is extreme: NIAID alone could represent 50% of potential revenue if delivery orders track ceiling.

TRI holds five major IDVs anchoring federal delivery. The largest is a $545.5 million single-award IDC with NIAID (awarded September 2021, through August 2028) for comprehensive and rapid-response biomedical research support, including clinical trial management, regulatory affairs, analytics, bioinformatics, quality assurance, and product storage and shipping across NIAID's Division of Clinical Research, Division of Intramural Research, and Vaccine Research Center. A second NIAID IDC valued at $364.6 million (December 2021, through November 2028) covers preclinical and translational vaccine development for HIV and other agents, with task areas spanning product storage, safety and immunogenicity studies, analytical development, CGMP manufacturing, stability testing, and scientific support; TRI competes for roughly 15 to 20 task orders annually at individual values up to $318 million. A third is an NCI multiple-award IDIQ (Cancer Trials Support Unit, $548 million combined ceiling across all awardees, with TRI holding a $5.56 million seat; awarded August 2022, through July 2027) for clinical trial support including protocol writing and site setup. A fourth, with ASPR, addresses clinical trial planning and execution for COVID vaccine development ($317.1 million delivery order awarded August 2023, through August 2028). A fifth is a single-award $2.5 million IDC with NIDA (awarded May 2025, through May 2030) for pharmacokinetic analysis and clinical pharmacology studies. Representative prime task-order work includes a $164.1 million NIAID/DAIDS regulatory support center delivery order (April 2024, through April 2031, cost-plus-fixed-fee), a $337 million NIAID Clinical Research Operations and Management Support definitive contract (April 2024, through March 2031), a $111.9 million NCI drug development support contract for the Cancer Therapy Evaluation Program (July 2022, through June 2032, with FY2024 SCI-reported 43.6 FTEs across 90,598 contractor hours at $85.79/hr derived rate), and a $31.9 million NIAID regulatory affairs support contract (July 2022, through June 2027, with FY2024 SCI-reported 15.1 FTEs across 31,360 contractor hours and one subcontractor accounting for 26% of hours).

Activity has been volatile and recently downtrend. Five-year award counts show 11 awards in 2022, declining to 6 in 2023, 5 in 2024, rising to 7 in 2025, and 2 in the first half of 2026. This represents a recompete-cliff risk: five prime awards (combined potential value $37.9 million) reach ultimate completion within the next twenty-four months and face recompete exposure. The near-term activity decline suggests pipeline tightness or a shift toward larger, multi-year task orders under existing IDVs rather than new award wins.

Service Contract Inventory data (covering federal service contracts above $150,000 threshold) shows SCI-reportable invoicing of $262.7 million across FY2022–FY2024. FY2022 invoiced $94.3 million across 390 FTEs; FY2023 invoiced $73.5 million across 383 FTEs; FY2024 invoiced $94.9 million across 355 FTEs. Government-paid hourly rates on SCI-reportable prime contracts span a broad spectrum, with a 10th percentile of $81.44/hr, median of $100.59/hr, and 90th percentile of $364.93/hr, reflecting a labor mix from junior scientists and program managers through senior science advisors and senior project leaders. TRI's GSA Schedule labor portfolio offers 22 active categories from $53.76/hr (junior biologist with master's degree) through $208.30/hr (senior science advisor with PhD and fifteen years' experience); no security-cleared positions are offered. The workforce remained relatively stable across the three-year SCI period, with reported FTEs declining modestly from 390 in FY2022 to 355 in FY2024, suggesting either rate increases on base activity or overhead absorption rather than headcount growth.

On prime contracts captured in SCI, TRI self-performs the vast majority of work—named subcontractors account for an average of 3% of total contractor hours across 81 SCI records. TRI names thirteen subcontractors across SCI-reportable prime contracts; two recent sub-awards appear as work under Digital Infuzion, LLC as prime on NIAID Clinical Research Management System (CRMS) support, with TRI providing clinical research management system support services on task orders exercised and funded through September 2026. TRI's model is direct-delivery, not subcontractor-driven.

Teaming: TRI operates almost entirely as a prime contractor and does not appear in the source data as a subcontractor to other major vendors. Its two named sub-awards (both under Digital Infuzion) represent minimal exposure and suggest infrequent use of TRI as a feeder vendor to larger primes. The company's competitive posture is independent prime on open-market federal health R&D contracts, not a teaming supply or sub-tier capacity builder.

Technical Resources International, Inc. (TRI) is a Hispanic woman-owned full service contract research organization (CRO). We provide product development services to the drug, biologic, and medical device community through the effective combination of scientific, clinical, information technology, and communications services.